Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Settles with LumiCyte, Molecular Analytical Systems over SELDI

NEW YORK, May 30 - Ciphergen Biosystems, LumiCyte, and Molecular Analytical Systems have settled their lawsuit over a mass spectrometry technology called SELDI-TOF, Ciphergen said yesterday.


Under the terms of the settlement, Ciphergen will pay revenue-based royalties of up to $10 million, over a 10-year period, to Molecular Analytical Systems. Ciphergen will also issue about 1.25 million shares to LumiCyte and pay the company about $3 million in cash.


In return, Ciphergen acquires Molecular Analytical's exclusive worldwide patent rights to surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Molecular Analytical licenses patents protecting the technology from Baylor College of Medicine. Moreover, LumiCyte has assigned all its rights relating to the technology, which it acquired from Molecular Analytical, to Ciphergen without restrictions.


For further information, see the company statement.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.